Latest news with #pharmacompanies
Yahoo
9 hours ago
- Business
- Yahoo
'Not How Numbers Work': Critics School Trump After Baffling New Claim
President Donald Trump is getting heat on social media for making a claim on Tuesday about cutting drug prices that's essentially mathematically impossible. Trump began promisingly enough with a complaint shared by Democrats and Republicans alike: the high cost of medication, and how much more Americans pay for some medications than patients in other countries. He promised to reduce those costs ― but to a very unlikely degree. 'We're gonna get the drug prices down. Not 30% or 40%, which would be great. Not 50% or 60%. No, we're gonna get them down 1,000%, 600%, 500%, 1,500%,' Trump said at a Republican dinner. 'Numbers that are not even thought to be achievable.' Critics quickly pointed out the reason those numbers are not thought to be achievable: reducing the price by 100% would make the drugs free. Reducing it by '1,000%, 600%, 500%, 1,500%,' as Trump said, would make the cost negative dollars ― with the drug company essentially paying people to take the medication. Several users asked Grok, the AI chatbot on X, if Trump's numbers made sense. Grok called Trump's claim ' mathematically impossible,' ' hyperbolic and not literal ' and ' total bullshit.' But Trump insisted he could use 'a certain talent that I have' to convince pharmaceutical companies that they have no choice but to reduce their prices. Trump also mentioned an executive order he signed in May to invoke 'most-favored nation' status in drug costs, which he says would ensure that drug companies can't charge Americans any more than what they charge patients in other nations. However, the details of that plan remain hazy, and at least one pharmaceutical CEO said discussions with the White House are ongoing and expected to take time. Trump on Tuesday insisted that his order will lead to those price cuts. 'We will have reduced drug prices by 1,000%, by 1,100, 1,200, 1,300, 1,400, 700, 600,' he said. 'Not 30 or 40 or 50%, but numbers the likes of which you've never even dreamed of before.' Trump's critics offered some free math lessons:
Yahoo
18 hours ago
- Business
- Yahoo
'Not How Numbers Work': Critics School Trump After Baffling New Claim
President Donald Trump is getting heat on social media for making a claim on Tuesday about cutting drug prices that's essentially mathematically impossible. Trump began promisingly enough with a complaint shared by Democrats and Republicans alike: the high cost of medication, and how much more Americans pay for some medications than patients in other countries. He promised to reduce those costs ― but to a very unlikely degree. 'We're gonna get the drug prices down. Not 30% or 40%, which would be great. Not 50% or 60%. No, we're gonna get them down 1,000%, 600%, 500%, 1,500%,' Trump said at a Republican dinner. 'Numbers that are not even thought to be achievable.' Critics quickly pointed out the reason those numbers are not thought to be achievable: reducing the price by 100% would make the drugs free. Reducing it by '1,000%, 600%, 500%, 1,500%,' as Trump said, would make the cost negative dollars ― with the drug company essentially paying people to take the medication. Several users asked Grok, the AI chatbot on X, if Trump's numbers made sense. Grok called Trump's claim 'mathematically impossible,' 'hyperbolic and not literal' and 'total bullshit.' But Trump insisted he could use 'a certain talent that I have' to convince pharmaceutical companies that they have no choice but to reduce their prices. Trump also mentioned an executive order he signed in May to invoke 'most-favored nation' status in drug costs, which he says would ensure that drug companies can't charge Americans any more than what they charge patients in other nations. However, the details of that plan remain hazy, and at least one pharmaceutical CEO said discussions with the White House are ongoing and expected to take time. Trump on Tuesday insisted that his order will lead to those price cuts. 'We will have reduced drug prices by 1,000%, by 1,100, 1,200, 1,300, 1,400, 700, 600,' he said. 'Not 30 or 40 or 50%, but numbers the likes of which you've never even dreamed of before.' Trump's critics offered some free math lessons: As someone who graduated from first grade, this is not how numbers work. — Hemant Mehta (@hemantmehta) July 23, 2025 Thank goodness this guy isn't negotiating the percentages we pay in tariffs. — Justin Wolfers (@JustinWolfers) July 23, 2025 Quite a trick if he can do it. Are we going into negative numbers where big Pharma pays me to take their drugs? — Dj Omega Mvp (@DjOmegaMVP) July 23, 2025 Hard to imagine this guy was found liable of fraud for making up numbers — MeidasTouch (@MeidasTouch) July 23, 2025 The economics department at Wharton must be incredibly proud of this man's fundamental understanding of basic math. — Franklin Leonard (@franklinleonard) July 23, 2025 Cant wait fill my next zpack at cvs and leave with a stack of their money — Ronnie (@Gem_Mint_Cards_) July 23, 2025 Getting paid to take drugs sounds awesome where do I sign up — TCL (@TitleTalkTCL) July 23, 2025 Universal Prescription Income. Your move, Yang — Roger Sollenberger (@SollenbergerRC) July 23, 2025 What kind of math is this? — Wu Tang is for the Children (@WUTangKids) July 23, 2025 And people wonder how this idiot bankrupted casinos. — Jo (@JoJoFromJerz) July 23, 2025 Negative drug prices are on the way ! 🤣🇺🇸 — Christopher Schultz (@nalyticsatwork) July 23, 2025 This is the fucking genius. — Fred Wellman (@FPWellman) July 23, 2025 — Dave Itzkoff (@ditzkoff) July 23, 2025 @realDonaldTrump is out here pitching drug deals like it's Shark Tank for Cartels:'I'm offering insulin for negative $300 and a lifetime supply of bleach injections… but only if you call in the next 15 minutes.'This QVC for crackheads. — Frank C (@FrankC164) July 23, 2025
Wall Street Journal
5 days ago
- Business
- Wall Street Journal
Readers Respond to Bill Gates on Overseas Health Aid
In his op-ed 'U.S. Aid for Global Health Is Saving Lives' (July 15), Bill Gates calls attention to how 'guaranteeing and pooling demand for HIV/AIDS relief . . . encourages pharmaceutical companies to compete in drug development and manufacturing.' Mr. Gates's altruism is admirable. But he wants U.S. taxpayers to supplement substantially his efforts, while acknowledging that the private sector can do the same job given the right incentives.
Yahoo
5 days ago
- Business
- Yahoo
Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors?
AstraZeneca PLC (NASDAQ:AZN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) has a strong lineup of drugs in development, which should help it navigate upcoming patent expirations. By the end of the first quarter, it had secured around 13 drug approvals or label updates. Among its most promising experimental treatments are two potential weight management drugs, AZD5004 and AZD6234. Overall, the company is working on nearly 200 programs in its research pipeline. In the first quarter of 2025, AstraZeneca PLC (NASDAQ:AZN) reported revenue of $13.6 billion, which showed a 7% growth from the same period last year. Total revenue has grown across all key regions, with core operating profit rising by 12%. The company is also planning to ramp up its investment in manufacturing and research in the U.S., building on its major R&D centers in Gaithersburg, Maryland, and Cambridge, Massachusetts. Overall, it is steadily moving closer to its goal of reaching $80 billion in total revenue by 2030. AstraZeneca PLC (NASDAQ:AZN) currently pays an interim dividend of $1.03 per share and has a dividend yield of 2.25%, as of July 17. It is one of the best dividend stocks in the pharma sector as the company has been paying regular dividends to shareholders for the past 32 years. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Times
16-07-2025
- Business
- Times
Trump threatens tariffs on big pharma ‘at the end of the month'
President Trump has threatened to impose tariffs on pharmaceuticals as soon as the end of the month as he steps up pressure on big pharma to shift manufacturing and investment to the US. 'Probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff,' he said. The president's latest remarks follow a threat last week to impose pharma import tariffs of as much as 200 per cent, but would first give companies up to 18 months to move more production back to the US. Trump's campaign to onshore more manufacturing to the US has led to volatility in pharma share prices this year and raised concerns about investment and jobs being sucked away from Europe and the UK.
